Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement

Endocrine Reviews

Volumn 35, Issue 3, 2014, Pages 341-375

  Pope, Harrison G ^a   Wood Jr , Ruth I ^b   Rogol, Alan ^c   Nyberg, Fred ^d   Bowers, Larry ^e   Bhasin, Shalender ^f  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e US Anti Doping Agency   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANDROSTENEDIOL; AMPHETAMINE; ANABOLIC AGENT; ANDROGEN; ANDROSTENEDIOL; ANDROSTENEDIONE; ANTIANEMIC AGENT; BOLDENONE; CANNABINOID; CENTRAL STIMULANT AGENT; CLENBUTEROL; COCAINE; DIAMORPHINE; DROSTANOLONE PROPIONATE; ESTR 4 ENE 3,17 DIONE; GROWTH HORMONE; INSULIN; METANDIENONE; METHYLTESTOSTERONE; METRIBOLONE; NANDROLONE; OXANDROLONE; PEPTIDE HORMONE; PERFORMANCE ENHANCING SUBSTANCE; PRASTERONE; STANOZOLOL; STEROID; TESTOSTERONE; TETRAHYDROGESTRINONE; TRENBOLONE; ERYTHROPOIETIN; HUMAN GROWTH HORMONE;

ALCOHOL CONSUMPTION; ATHLETIC PERFORMANCE; CARDIOVASCULAR DISEASE; DIET SUPPLEMENTATION; DOPING; DRUG ABUSE; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; HEALTH BEHAVIOR; HIGH RISK BEHAVIOR; HUMAN; INFECTION; INFECTIOUS COMPLICATION; KIDNEY DISEASE; LIVER DISEASE; MEDICAL SOCIETY; MENTAL DISEASE; METABOLIC DISORDER; MONOAMINERGIC SYSTEM; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SPORT INJURY; WITHDRAWAL SYNDROME; STANDARDS;

ANABOLIC AGENTS; ANDROGENS; ERYTHROPOIETIN; HUMAN GROWTH HORMONE; HUMANS; INSULIN; PERFORMANCE-ENHANCING SUBSTANCES; SOCIETIES, MEDICAL;

EID: 84901493477     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2013-1058     Document Type: Review

References (421)

1. Pope HG Jr, Kanayama G, Hudson JI. Risk factors for illicit anabolic-androgenic steroid use in male weightlifters: a cross-sectional cohort study. Biol Psychiatry. 2012;71: 254-261.
2. Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38(4): 644-651.
3. Wilson JD. Androgen abuse by athletes. Endocr Rev. 1988; 9(2):181-199.
4. Handelsman DJ. Commentary: androgens and "anabolic steroids": the one-headed janus. Endocrinology. 2011; 152(5):1752-1754.
5. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148(1):363-373.
6. Schmidt A, Kimmel DB, Bai C, et al. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010;285(22): 17054-17064.
7. Schmidt A, Harada S, Kimmel DB, et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem. 2009;284(52):36367-36376.
8. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6: e010.
9. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue- selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 2008; 22(11):2448-2465.
10. Jasuja R, Costello JC, Singh R, et al. Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy. Aging Cell. 2014;13(2):303-310.
11. Gao W, Dalton JT. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5α-reductase? Mol Interv. 2007;7(1):10-13.
12. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232-240.
13. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146-159.
14. Brennan BP, Kanayama G, Hudson JI, Pope HG Jr. Human growth hormone abuse in male weightlifters. Am J Addict. 2011;20(1):9-13.
15. Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. Weightlifting's risky new trend: a case series of 41 insulin users. Curr Sports Med Rep. 2012;11(4):176-179.
16. The 2013 list of prohibited substances and methods. World Anti-Doping Agency website. http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/. Accessed January 30, 2013.
17. The world anti-doping code. World-Anti-Doping Agency website. http://www.wada-ama.org/en/world-anti-dopingprogram/sports-and-anti-doping-organizations/the-code. Accessed January 30, 2013.
18. Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1-2):1-12.
19. Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates [published online September 20, 2013]. AmJ Addict. doi:10.1111/j.1521-0391.2013.12118.x.
20. Pope HG, Kanayama G. Can you tell if your patient is using anabolic steroids? Curr Psychiatry Primary Care. 2005;1: 28-34.
21. Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users' attitudes towards physicians. Addiction. 2004;99(9):1189-1194.
22. Dawson R. Drugs in sport: the role of the physician. J Endocrinol. 2001;170:55-61.
23. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med. 2002;32(5):285-296.
24. Pope HG, Kanayama G. Treatment of anabolic-androgenic steroid related disorders. In: Galanter M, Kleber H, Brady K, eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. 5th ed. Washington, DC: American Psychiatric Association; in press.
25. Drug Abuse Warning Network(DAWN). Substance Abuse and Mental Health Services Administration website. http://www.samhsa.gov/data/DAWN.aspx. Accessed March 14, 2013.
26. Mitchell GJ. Report to the Commissioner of Baseball of an independent investigation into the illegal use of steroids and other performance-enhancing substances by players in Major League Baseball. Office of the Commissioner of Baseball; 2007.
27. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med. 1995;19(5):326-340.
28. Brown-Séquard C. Des effets produits chez l'homme par des injections souscutanées d'un liquide retiré des testicules frais de cobaye et de chien. C R Séance Soc Biol. 1889: 415-422, 429-431.
29. Kahn A. Regaining lost youth: the controversial and colorful beginnings of hormone replacement therapy in aging. J Gerontol A Biol Sci Med Sci. 2005;60(2):142-147.
30. Freeman ER, Bloom DA, McGuire EJ. A brief history of testosterone. J Urol. 2001;165(2):371-373.
31. Boje O. Doping. Bulletin of Health Organization of the League of Nations. 1939;8:439-469.
32. Wade N. Anabolic steroids: doctors denounce them, but athletes aren't listening. Science. 1972;176:1399-1403.
33. Bahrke MS, Yesalis CE. Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol. 2004;4(6):614-620.
34. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem. 1997; 43(7):1262-1279.
35. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. RapidCommunMass Spectrom. 2004;18(12):1245-1249.
36. Jasuja R, Catlin DH, Miller A, et al. Tetrahydrogestrinone is an androgenic steroid that stimulates androgen receptormediated, myogenic differentiation in C3H10T1/2 multipotent mesenchymal cells and promotes muscle accretion in orchidectomized male rats. Endocrinology. 2005; 146(10):4472-4478.
37. Sekera MH, Ahrens BD, Chang YC, Starcevic B, Georgakopoulos C, Catlin DH. Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun Mass Spectrom. 2005;19(6):781-784.
38. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: overview of key findings, 2012. Monitoring the Future website. http://www.monitoringthefuture.org/data/12data/pr12t1.pdf. Accessed March 12, 2013.
39. Cohen J, Collins R, Darkes J, Gwartney D. Aleague of their own: demographics, motivations and patterns of use of 1, 955 male adult non-medical anabolic steroid users in the United States. J Int Soc Sports Nutr. 2007;4:12.
40. Carter A, Flueck M. A polymerase chain reaction-based methodology to detect gene doping. Eur J Appl Physiol. 2012;112(4):1527-1536.
41. Kanayama G, Boynes M, Hudson JI, Field AE, Pope HG, Jr. Anabolic steroid abuse among teenage girls: an illusory problem? Drug Alcohol Depend. 2007;88(2-3):156-162.
42. Brower KJ, Eliopulos GA, Blow FC, Catlin DH, Beresford TP. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. Am J Psychiatry. 1990;147(4):510-512.
43. Copeland J, Peters R, Dillon P. Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend. 2000; 60(1):91-96.
44. Gridley DW, Hanrahan SJ. Anabolic-androgenic steroid use among male gymnasium participants: knowledge and motives. Sports Health. 1994;12:11-14.
45. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder Addiction. 2009;104(12):1966-1978.
46. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. AmJ Psychiatry. 2009;166(6):642-645.
47. Malone DA Jr, DimeffRJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolicandrogenic steroid users. Clin J Sport Med. 1995;5(1):25-31.
48. Midgley SJ, Heather N, Davies JB. Dependence-producing potential of anabolic-androgenic steroids. Addict Res. 1999;7:539-550.
49. Perry PJ, Lund BC, Deninger MJ, Kutscher EC, Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin J Sport Med. 2005;15(5):326-330.
50. Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32:910-919.
51. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. Acontrolled study of 160 athletes. Arch Gen Psychiatry. 1994;51(5):375-382.
52. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2010. HIV Surveillance Supplemental Report, Volume 17, Number 3 (Part A). Centers for Disease Control and Prevention website. http://www. cdc.gov/hiv/library/reports/surveillance/. Accessed January 5, 2014.
53. National diabetes statistics, 2011. U.S. Department of Health and Human Services website. http://diabetes. niddk.nih.gov/dm/pubs/statistics/index.aspx?controlPubs. Accessed March 14, 2013.
54. Hakansson A, Mickelsson K, Wallin C, Berglund M. Anabolic androgenic steroids in the general population: user characteristics and associations with substance use. Eur Addict Res. 2012;18(2):83-90.
55. Doping in Sweden: an inventory of its spread, consequences, and interventions. Trans. Semantx AB. Stockholm: Strömberg. Swedish National Institute of Public Health.
56. Mattila VM, Parkkari J, Laakso L, Pihlajamäki H, Rimpela A. Use of dietary supplements and anabolic-androgenic steroids among Finnish adolescents in 1991-2005. Eur J Public Health. 2010;20(3):306-311.
57. Leifman H, Rehman C. Prevalence of doping among gymnasium clients in Stockholm County [in Swedish]. Stockholm, Sweden: Stockholm förebyggare alcohol- och drogproblem (STAD); 2008.
58. Pallesen S, Jøsendal O, Johnsen BH, Larsen S, Molde H. Anabolic steroid use in high school students. Subst Use Misuse. 2006;41(13):1705-1717.
59. Nilsson S, Spak F, Marklund B, Baigi A, Allebeck P. Attitudes and behaviors with regards to androgenic anabolic steroids among male adolescents in a county of Sweden. Subst Use Misuse. 2004;39(8):1183-1197.
60. Galduróz JC, Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country-2001. Addict Behav. 2005; 30(3):545-556.
61. Galduróz JCF, Noto AR, Fonseca AM, Carlini EA. Levantamento Nacional Sobre o Consumo de Drogas Psicotrópicas entre Estudantes do Ensino Fundamental e Médio da Rede Pública de Ensino nas 27 Capitais Brasileiras-2004. São Paulo, Brazil: Centro Brasileiro de Informações sobre Drogas Psicotrópicas. http://www.cebrid.epm.br/levantamento_ brasil2/index.htm. Accessed January 5, 2014.
62. Dunn M, White V. The epidemiology of anabolic-androgenic steroid use among Australian secondary school students. J Sci Med Sport. 2011;14(1):10-14.
63. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur J Intern Med. 2006;17(7):479-484.
64. Australian Institute of Health and Welfare. 2010 National Drug Strategy Household Survey Report. Canberra, Australia: Australian Institute of Health and Welfare; 2011.
65. Smith K, Flatley J, eds. Drug use declared: Findings from the 2010/11 British Crime Survey - England and Wales. London: British Home Office. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147938/drugs-misuse-dec-1112-pdf.pdf. Accessed January 5, 2014.
66. Wanjek B, Rosendahl J, Strauss B, Gabriel HH. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int J Sports Med. 2007;28(4):346-353.
67. Racho D, Pokrywka L, Suchecka-Racho K. Prevalence and risk factors of anabolic-androgenic steroids (AAS) abuse among adolescents and young adults in Poland. Soz Praventivmed. 2006;51(6):392-398.
68. Kokkevi A, Fotiou A, Chileva A, Nociar A, Miller P. Daily exercise and anabolic steroids use in adolescents: a crossnational European study. Subst Use Misuse. 2008;43(14): 2053-2065.
69. Kanayama G, Hudson JI, Pope HG Jr. Culture, psychosomatics and substance abuse: the example of body image drugs. Psychother Psychosom. 2012;81(2):73-78.
70. Yang CF, Gray P, Pope HG Jr. Male body image in Taiwan versus the West: Yanggang Zhiqi meets the Adonis complex. Am J Psychiatry. 2005;162(2):263-269.
71. Skarberg K, Nyberg F, Engstrom I. Multisubstance use as a feature of addiction to anabolic-androgenic steroids. Eur Addict Res. 2009;15(2):99-106.
72. Arvary D, Pope HG Jr. Anabolic-androgenic steroids as a gateway to opioid dependence. N Engl J Med. 2000; 342(20):1532.
73. Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci. 2000;45(1):16-23.
74. Wines JD, Jr., Gruber AJ, Pope HG, Jr., Lukas SE. Nalbuphine hydrochloride dependence in anabolic steroid users. Am J Addict. 1999;8(2):161-164.
75. Kanayama G, Cohane GH, Weiss RD, Pope HG. Past anabolic- androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry. 2003;64(2):156-160.
76. Tennant F, Black DL, Voy RO. Anabolic steroid dependence with opioid-type features. N Engl J Med. 1988; 319(9):578.
77. Kanayama G, Pope HG Jr. Illicit use of androgens and other hormones: recent advances. Curr Opin Endocrinol Diabetes Obes. 2012;19(3):211-219.
78. Dodge T, Hoagland MF. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. Drug Alcohol Depend. 2011;114(2-3):100-109.
79. Kanayama G, Kean J, Hudson JI, Pope HG. Cognitive deficits in long-term anabolic-androgenic steroid users. Drug Alcohol Depend. 2013;130(1-3):208-214.
80. Pope HG, Kean J, Nash A, et al. A diagnostic interview module for anabolic-androgenic steroid dependence: preliminary evidence of reliability and validity. Exp Clin Psychopharmacol. 2010;18:203-213.
81. Cicero TJ, O'Connor LH. Abuse liability of anabolic steroids and their possible role in the abuse of alcohol, morphine, and other substances. NIDA Res Monogr. 1990; 102:1-28.
82. Johansson P, Lindqvist A, Nyberg F, Fahlke C. Anabolic androgenic steroids affects alcohol intake, defensive behaviors and brain opioid peptides in the rat. Pharmacol Biochem Behav. 2000;67(2):271-279.
83. Kindlundh AM, Lindblom J, Bergström L, Wikberg JE, Nyberg F. The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. Eur J Neurosci. 2001;13(2):291-296.
84. Le Grevès P, Zhou Q, Huang W, Nyberg F. Effect of combined treatment with nandrolone and cocaine on the NMDAreceptor gene expression in the rat nucleus accumbens and periaqueductal gray. Acta Psychiatr Scand Suppl. 2002;412:129-132.
85. Steensland P, Hallberg M, Kindlundh A, Fahlke C, Nyberg F. Amphetamine-induced aggression is enhanced in rats pre-treated with the anabolic androgenic steroid nandrolone decanoate. Steroids. 2005;70(3):199-204.
86. Hildebrandt T, Lai JK, Langenbucher JW, Schneider M, Yehuda R, PfaffDW. The diagnostic dilemma of pathological appearance and performance enhancing drug use. Drug Alcohol Depend. 2011;114(1):1-11.
87. Kanayama G, Hudson JI, Pope HG. Illicit anabolic-androgenic steroid use. Horm Behav. 2010;58(1):111-121. PMCID 2883629.
88. Summers J. Steroids 101. Aurora, CO: Anabolics.com Inc.; 2003.
89. Midgley SJ, Heather N, Best D, Henderson D, McCarthy S, Davies JB. Risk behaviours for HIV and hepatitis infection among anabolic-androgenic steroid users. AIDS Care. 2000;12(2):163-170.
90. Larance B, Degenhardt L, Copeland J, Dillon P. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug Alcohol Rev. 2008;27(6):679-686.
91. Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend. 2002;65(3):303-308.
92. Rich JD, Dickinson BP, Feller A, Pugatch D, Mylonakis E. The infectious complications of anabolic-androgenic steroid injection. Int J Sports Med. 1999;20(8):563-566.
93. Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction. 2002;97(2):195-203.
94. Hoffman JR, Kraemer WJ, Bhasin S, et al. Position standon androgen and human growth hormone use. J Strength Cond Res. 2009;23(5 Suppl):S1-S59.
95. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7.
96. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000; 283(6):763-770.
97. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181.
98. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosteroneinduced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154-E164.
99. Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosteroneinduced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. AmJ Physiol Endocrinol Metab. 2003;285(1):E197-E205.
100. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144(11):5081-5088.
101. Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex withβ-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology. 2006;147(1):141-154.
102. Braga M, Bhasin S, Jasuja R, Pervin S, Singh R. Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. Mol Cell Endocrinol. 2012;350(1):39-52.
103. Serra C, Bhasin S, Tangherlini F, et al. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen- responsive muscle. Endocrinology. 2011;152(1): 193-206.
104. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003;88(4):1478-1485.
105. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307(9):931-939.
106. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919.
107. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008;296(1-2):32-40.
108. Singh R, Bhasin S, Braga M, et al. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/β-catenin and follistatin/transforming growth factor-β signaling pathways. Endocrinology. 2009; 150(3):1259-1268.
109. Leslie M, Forger NG, Breedlove SM. Sexual dimorphism and androgen effects on spinal motoneurons innervating the rat flexor digitorum brevis. Brain Res. 1991;561(2): 269-273.
110. Blanco CE, Popper P, Micevych P. Anabolic-androgenic steroid induced alterations in choline acetyltransferase messenger RNA levels of spinal cord motoneurons in the male rat. Neuroscience. 1997;78(3):873-882.
111. Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, γ-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25(5):756-761.
112. Vogt AM, Geyer H, Jahn L, Schänzer W, Kübler W. Cardiomyopathy associated with uncontrolled self medication of anabolic steroids [in German]. Z Kardiol. 2002;91(4): 357-362.
113. Ferenchick GS. Association of steroid abuse with cardiomyopathy in athletes. Am J Med. 1991;91(5):562.
114. Schollert PV, Bendixen PM. Dilated cardiomyopathy in a user of anabolic steroids [in Danish]. Ugeskr Laeger. 1993; 155(16):1217-1218.
115. Ahlgrim C, Guglin M. Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. J Card Fail. 2009;15(6):496-500.
116. Bispo M, Valente A, Maldonado R, et al. Anabolic steroidinduced cardiomyopathy underlying acute liver failure in a young bodybuilder. World J Gastroenterol. 2009;15(23): 2920-2922.
117. Halvorsen S, Thorsby PM, Haug E. Acute myocardial infarction in a young man who had been using androgenic anabolic steroids [in Norwegian]. TidsskrNorLaegeforen. 2004;124(2):170-172.
118. Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001; 125(2):253-255.
119. Godon P, Bonnefoy E, Guerard S, et al. Myocardial infarction and anabolic steroid use. Acase report [in French]. Arch Mal Coeur Vaiss. 2000;93(7):879-883.
120. Varriale P, Mirzai-tehrane M, Sedighi A. Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Pharmacotherapy. 1999;19(7):881-884.
121. Fisher M, Appleby M, Rittoo D, Cotter L. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract. 1996;50(4):222-223.
122. Kennedy C. Myocardial infarction in association with misuse of anabolic steroids. Ulster Med J. 1993;62(2):174-176.
123. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. Med J Aust. 1993;158(5):346-348.
124. Ferenchick GS, Adelman S. Myocardial infarction associated with anabolic steroid use in a previously healthy 37-year-old weight lifter. Am Heart J. 1992;124(2):507-508.
125. McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62(1): 164.
126. Huie MJ. An acute myocardial infarction occurring in an anabolic steroid user. Med Sci Sports Exerc. 1994;26(4): 408-413.
127. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol. 1994;44(2):171-174.
128. Lisiewicz J, Fijalkowski P, Sankowski J. Ischemic cerebral stroke and anabolic steroids (case report) [in Polish]. Neurol Neurochir Pol. 1999;32(Suppl 6):137-139.
129. Shimada Y, Yoritaka A, Tanaka Y, et al. Cerebral infarction in a young man using high-dose anabolic steroids. J Stroke Cerebrovasc Dis. 2012;21(8):906.e9-911.e9.
130. Kennedy MC, Corrigan AB, Pilbeam ST. Myocardial infarction and cerebral haemorrhage in a young body builder taking anabolic steroids. AustNZJ Med. 1993;23(6):713.
131. Lau DH, Stiles MK, John B, Shashidhar, Young GD, Sanders P. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol. 2007;117(2):e86-e87.
132. Furlanello F, Bentivegna S, Cappato R, De Ambroggi L. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J. 2003;4(12):829-837.
133. Mewis C, Spyridopoulos I, Kühlkamp V, Seipel L. Manifestation of severe coronary heart disease after anabolic drug abuse. Clin Cardiol. 1996;19(2):153-155.
134. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851-857.
135. Tischer KH, Heyny-von Haussen R, Mall G, Doenecke P. Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids [in German]. Z Kardiol. 2003;92(4):326-331.
136. Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart. 2002;88(4):342.
137. McCarthy K, Tang AT, Dalrymple-Hay MJ, Haw MP. Ventricular thrombosis and systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg. 2000;70(2):658-660.
138. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic- anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci. 1992;303(2): 78-82.
139. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses. 1991; 35(1):27-31.
140. Krieg A, Scharhag J, Albers T, Kindermann W, Urhausen A. Cardiac tissue Doppler in steroid users. Int J SportsMed. 2007;28(8):638-643.
141. Vanberg P, Atar D. Androgenic anabolic steroid abuse and the cardiovascular system. Handb Exp Pharmacol. 2010; 195:411-457.
142. Nascimento JH, Medei E. Cardiac effects of anabolic steroids: hypertrophy, ischemia and electrical remodelling as potential triggers of sudden death. Mine Rev Med Chem. 2011;11(5):425-429.
143. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901.
144. Angell PJ, Chester N, Sculthorpe N, Whyte G, George K, Somauroo J. Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician. Br J Sports Med. 2012;46(Suppl 1):i78-i84.
145. Far HR, Ågren G, Thiblin I. Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovasc Pathol. 2012;21(4): 312-316.
146. Montisci M, El Mazloum R, Cecchetto G, et al. Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci Int. 2012;217:e13-e18.
147. Sculthorpe N, Grace F, Jones P, Davies B. Evidence of altered cardiac electrophysiology following prolonged androgenic anabolic steroid use. Cardiovasc Toxicol. 2010; 10(4):239-243.
148. Maior AS, Carvalho AR, Marques-Neto SR, Menezes P, Soares PP, Nascimento JH. Cardiac autonomic dysfunction in anabolic steroid users. Scand J Med Sci Sports. 2013;23(5):548-555.
149. Maior AS, Menezes P, Pedrosa RC, Carvalho DP, Soares PP, Nascimento JH. Abnormal cardiac repolarization in anabolic androgenic steroid users carrying out submaximal exercise testing. Clin Exp Pharmacol Physiol. 2010; 37(12):1129-1133.
150. Medei E, Marocolo M, Rodrigues Dde C, et al. Chronic treatment with anabolic steroids induces ventricular repolarization disturbances: cellular, ionic and molecular mechanism. J Mol Cell Cardiol. 2010;49(2):165-175.
151. Montisci R, Cecchetto G, Ruscazio M, et al. Early myocardial dysfunction after chronic use of anabolic androgenic steroids: combined pulsed-wave tissue Doppler im- aging and ultrasonic integrated backscatter cyclic variations analysis. J Am Soc Echocardiogr. 2010;23(5): 516-522.
152. Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation. 2010;3:472-476.
153. Hassan NA, Salem MF, Sayed MA. Doping and effects of anabolic androgenic steroids on the heart: histological, ultrastructural, and echocardiographic assessment in strength athletes. Hum Exp Toxicol. 2009;28(5):273-283.
154. D'Andrea A, Caso P, Salerno G, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med. 2007;41(3):149-155.
155. Nottin S, Nguyen LD, Terbah M, Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol. 2006;97(6):912-915.
156. Kasikcioglu E, Oflaz H, Umman B, Bugra Z. Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol. 2009;134(1):123-125.
157. Nyberg F, Hallberg M. Interactions between opioids and anabolic androgenic steroids: implications for the development of addictive behavior. Int Rev Neurobiol. 2012; 102:189-206.
158. Luijkx T, Velthuis BK, Backx FJ, et al. Anabolic androgenic steroid use is associated with ventricular dysfunction on cardiac MRI in strength trained athletes. Int J Cardiol. 2013;167(3):664-668.
159. Kasikcioglu E, Oflaz H, Arslan A, et al. Aortic elastic properties in athletes using anabolic-androgenic steroids. Int J Cardiol. 2007;114(1):132-134.
160. Rothman R, Weiner R, Pope H Jr, et al. Anabolic androgenic steroid induced myocardial toxicity: an evolving problem in an ageing population. BMJ Case Rep. 2011; pii:bcr0520114280.
161. Riezzo I, De Carlo D, Neri M, Nieddu A, Turillazzi E, Fineschi V. Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exerciseinduced cardiotoxicity. Mine Rev Med Chem. 2011;11(5): 409-424.
162. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004; 38(3):253-259.
163. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
164. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989;261(8):1165-1168.
165. Fontana K, Oliveira HC, Leonardo MB, Mandarim-de-Lacerda CA, da Cruz-Höfling MA. Adverse effect of the anabolic-androgenic steroid mesterolone on cardiac remodelling and lipoprotein profile is attenuated by aerobicz exercise training. Int J Exp Pathol. 2008;89(5):358-366.
166. Santora LJ, Marin J, Vangrow J, M et al. Coronary calcification in body builders using anabolic steroids. Prev Cardiol. 2006;9(4):198-201.
167. Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21(3):225-227.
168. Pope HG, Katz DL. Psychiatric effects of exogenous anabolic- androgenic steroids. In: Wolkowitz OM, Rothschild AJ, eds. Psychoneuroendocrinology: The Scientific Basis of Clinical Practice. Washington, DC: American Psychiatric Press; 2003:331-358.
169. Hall RC, Hall RC, Chapman MJ. Psychiatric complications of anabolic steroid abuse. Psychosomatics. 2005; 46(4):285-290.
170. Talih F, Fattal O, Malone D Jr. Anabolic steroid abuse: psychiatric and physical costs. Cleve Clin J Med. 2007; 74(5):341-344, 346, 349-352.
171. Parrott AC, Choi PY, Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J Sports Med Phys Fitness. 1994;34(3):292-298.
172. Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry. 1988;145(4):487-490.
173. Cooper CJ, Noakes TD, Dunne T, Lambert MI, Rochford K. A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids. Br J Sports Med. 1996;30(3):246-250.
174. Bahrke MS, Wright JE, Strauss RH, Catlin DH. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am J Sports Med. 1992;20(6):717-724.
175. Choi PY, Pope HG Jr. Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry. 1994;6(1):21-25.
176. Midgley SJ, Heather N, Davies JB. Levels of aggression among a group of anabolic-androgenic steroid users. Med Sci Law. 2001;41(4):309-314.
177. Moss H, Panzak G, Tarter R. Personality, mood, and psychiatric symptoms among anabolic steroid users. AmJ Addict. 1992;1:315-324.
178. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes. A case series analysis. Am J Sports Med. 1990;18(4):422-428.
179. Perry PJ, Kutscher EC, Lund BC, Yates WR, Holman TL, Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci. 2003;48(3):646-651.
180. Yates WR, Perry P, Murray S. Aggression and hostility in anabolic steroid users. Biol Psychiatry. 1992;31(12): 1232-1234.
181. Choi PY, Parrott AC, Cowan D. High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Hum Psychopharmacol. 1990;5:349-356.
182. Fudala PJ, Weinrieb RM, Calarco JS, Kampman KM, Boardman C. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies. Ann Clin Psychiatry. 2003;15(2):121-130.
183. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur Psychiatry. 2006; 21(8):551-562.
184. Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadji-christodoulou CS, Toli PN. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur Psychiatry. 2006;21(8):563-569.
185. Wilson-Fearon C, Parrott AC. Multiple drug use and dietary restraint in a Mr. Universe competitor: psychobiological effects. Percept Mot Skills. 1999;88(2):579-580.
186. Pope HG, Brower KJ. Anabolic-androgenic steroid-related disorders. In: Sadock B, Sadock V, eds. Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams, Wilkins; 2009:1419-1431.
187. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974-984.
188. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of highdose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003;28(3):317-331.
189. Schmidt PJ, Berlin KL, Danaceau MA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004;61(10):997-1004.
190. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. Oneyear follow-up study of the association between chemical castration, sex hormones, β-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8): 1071-1081.
191. Bahrke MS, Yesalis CE 3rd. Weight training. A potential confounding factor in examining the psychological and behavioural effects of anabolic-androgenic steroids. Sports Med. 1994;18(5):309-318.
192. Bahrke MS, Yesalis CE 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic- androgenic steroids. An update. Sports Med. 1996; 22(6):367-390.
193. Björkqvist K, Nygren T, Björklund AC, Björkqvist SE. Testosterone intake and aggressiveness: real effect or anticipation? Aggressive Behavior. 1994;20(1):17-26.
194. Riem K, Hursey K. Using anabolic-androgenic steroids to enhance physique and performance: effects on moods and behavior Clin Psychol Rev. 1995;15:235-256.
195. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry. 2000;57(2):133-140; discussion 155-136.
196. Clark AS, Henderson LP. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev. 2003;27(5):413-436.
197. Melloni RH Jr, Connor DF, Hang PT, Harrison RJ, Ferris CF. Anabolic-androgenic steroid exposure during adolescence and aggressive behavior in golden hamsters. Physiol Behav. 1997;61(3):359-364.
198. DeLeon KR, Grimes JM, Melloni RH Jr. Repeated anabolic- androgenic steroid treatment during adolescence increases vasopressin V(1A) receptor binding in Syrian hamsters: correlation with offensive aggression. Horm Behav. 2002;42(2):182-191.
199. Conacher GN, Workman DG. Violent crime possibly associated with anabolic steroid use. Am J Psychiatry. 1989; 146(5):679.
200. Pope HG Jr, Katz DL. Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry. 1990;51(1):28-31.
201. Pope HG Jr, Kouri EM, Powell KF, Campbell C, Katz DL. Anabolic-androgenic steroid use among 133 prisoners. Compr Psychiatry. 1996;37(5):322-327.
202. Dalby JT. Brief anabolic steroid use and sustained behavioral reaction. Am J Psychiatry. 1992;149(2):271-272.
203. Schulte HM, Hall MJ, Boyer M. Domestic violence associated with anabolic steroid abuse. AmJ Psychiatry. 1993; 150(2):348.
204. Stanley A, Ward M. Anabolic steroids-the drugs that give and take away manhood. A case with an unusual physical sign. Med Sci Law. 1994;34(1):82-83.
205. Thiblin I, Kristiansson M, Rajs J. Anabolic androgenic steroids and behavioural patternsamongviolent offenders. J Forensic Psychiatry. 1997;8:299-310.
206. Thiblin I, Pärlklo T. Anabolic androgenic steroids and violence. Acta Psychiatr Scand Suppl. 2002;412:125-128.
207. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol. 2005;19(1):27-44.
208. Klötz F, Petersson A, Isacson D, Thiblin I. Violent crime and substance abuse: A medico-legal comparison between deceased users of anabolic androgenic steroids and abusers of illicit drugs. Forensic Sci Int. 2007;173(1):57-63.
209. Klötz F, Petersson A, Hoffman O, Thiblin I. The significance of anabolic androgenic steroids in a Swedish prison population. Compr Psychiatry. 2010;51(3):312-318.
210. Lundholm L, Käll K, Wallin S, Thiblin I. Use of anabolic androgenic steroids in substance abusers arrested for crime. Drug Alcohol Depend. 2010;111(3):222-226.
211. Friedl KE, Dettori JR, Hannan CJ Jr, Patience TH, Plymate SR. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J Steroid Biochem Mol Biol. 1991;40(4-6):607-612.
212. Friedl KE, Jones RE, Hannan CJ Jr, Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab. 1989;68(5):971-975.
213. Hannan CJ Jr, Friedl KE, Zold A, Kettler TM, Plymate SR. Psychological and serum homovanillic acid changes inmen administered androgenic steroids. Psychoneuroendocrinology. 1991;16(4):335-343.
214. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990;70(1): 282-287.
215. Forbes GB, Porta CR, Herr BE, Griggs RC. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA. 1992; 267(3):397-399.
216. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994;79(2):561-567.
217. Ip EJ, Barnett MJ, Tenerowicz MJ, Perry PJ. The Anabolic 500 survey: characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. Pharmacotherapy. 2011;31(8):757-766.
218. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA. 1993;269(21): 2760-2764.
219. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men-a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3754-3758.
220. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol psychiatry. 1999;45(3):254-260.
221. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend. 1995;40(1):73-79.
222. Maldonado R, Blendy JA, Tzavara E, et al. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science. 1996;273(5275):657-659.
223. Guidance for industry. Estimating themaximumsafe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Food and Drug Administration website. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed July 11, 2013.
224. Oberlander JG, Henderson LP. The Sturm und Drang of anabolic steroid use: angst, anxiety, and aggression. Trends Neurosci. 2012;35(6):382-392.
225. Rejeski WJ, Brubaker PH, Herb RA, Kaplan JR, Koritnik D. Anabolic steroids and aggressive behavior in cynomolgus monkeys. J Behav Med. 1988;11(1):95-105.
226. Lumia AR, Thorner KM, McGinnis MY. Effects of chronically high doses of the anabolic androgenic steroid, testosterone, on intermale aggression and sexual behavior in male rats. Physiol Behav. 1994;55(2):331-335.
227. Grimes JM, Ricci LA, Melloni RH Jr. Glutamic acid decarboxylase (GAD65) immunoreactivity in brains of aggressive, adolescent anabolic steroid-treated hamsters. Horm Behav. 2003;44(3):271-280.
228. Steensland P, Blakely G, Nyberg F, Fahlke C, Pohorecky LA. Anabolic androgenic steroid affects social aggression and fear-related behaviors in male pair-housed rats. Horm Behav. 2005;48(2):216-224.
229. Fischer SG, Ricci LA, Melloni RH Jr. Repeated anabolic/androgenic steroid exposure during adolescence alters phosphate-activated glutaminase and glutamate receptor 1 (GluR1) subunit immunoreactivity in Hamster brain: correlation with offensive aggression. Behav Brain Res. 2007; 180(1):77-85.
230. Carrillo M, Ricci LA, Melloni RH. Glutamate and the aggression neural circuit in adolescent anabolic steroidtreated Syrian hamsters (Mesocricetus auratus). Behav Neurosci. 2011;125(5):753-763.
231. Breuer ME, McGinnis MY, Lumia AR, Possidente BP. Aggression in male rats receiving anabolic androgenic steroids: effects of social and environmental provocation. Horm Behav. 2001;40(3):409-418.
232. McGinnis MY, Lumia AR, Breuer ME, Possidente B. Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids. Horm Behav. 2002; 41(1):101-110.
233. Hallberg M, Johansson P, Kindlundh AM, Nyberg F. Anabolic- androgenic steroids affect the content of substance P and substance P(1-7) in the rat brain. Peptides. 2000; 21(6):845-852.
234. Le Grevès P, Huang W, Johansson P, Thörnwall M, Zhou Q, Nyberg F. Effects of an anabolic-androgenic steroid on the regulation of the NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of the male rat. Neurosci Lett. 1997;226(1):61-64.
235. Henderson LP, Penatti CA, Jones BL, Yang P, Clark AS. Anabolic androgenic steroids and forebrain GABAergic transmission. Neuroscience. 2006;138(3):793-799.
236. Kindlundh AM, Lindblom J, Bergström L, Nyberg F. The anabolic-androgenic steroid nandrolone induces alterations in the density of serotonergic 5HT1B and 5HT2 receptors in the male rat brain. Neuroscience. 2003;119(1): 113-120.
237. Keleta YB, Lumia AR, Anderson GM, McGinnis MY. Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin. Brain Res. 2007; 1132(1):129-138.
238. Kindlundh AM, Hagekull B, Isacson DG, Nyberg F. Adolescent use of anabolic-androgenic steroids and relations to self-reports of social, personality and health aspects. Eur J Public Health. 2001;11(3):322-328.
239. Schwartzer JJ, Melloni RH Jr. Anterior hypothalamic dopamineD2receptors modulate adolescent anabolic/androgenic steroid-induced offensive aggression in the Syrian hamster. Behav Pharmacol. 2010;21(4):314-322.
240. Lindqvist AS, Johansson-Steensland P, Nyberg F, Fahlke C. Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. Behav Brain Res. 2002;133(1):21-29.
241. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend. 2010;109:6-13.
242. Pope HG Jr, Gruber AJ, Choi P, Olivardia R, Phillips KA. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics. 1997;38(6):548-557.
243. Kanayama G, Pope HG Jr. Gods, men, and muscle dysmorphia. Harvard Rev Psychiatry. 2011;19:95-98.
244. Cole JC, Smith R, Halford JC, WagstaffGF. Apreliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology. 2003; 166(4):424-429.
245. Pope HG Jr, Katz DL, Hudson JI. Anorexia nervosa and "reverse anorexia" among 108 male bodybuilders. Compr Psychiatry. 1993;34(6):406-409.
246. Association AP. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
247. Kanayama G, Barry S, Hudson JI, Pope HG Jr. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am J Psychiatry. 2006;163(4):697-703.
248. Chung B. Muscle dysmorphia in weightlifters. Br J Sports Med. 2003;37(3):280-281.
249. Olivardia R, Pope HG Jr, Hudson JI. Muscle dysmorphia in male weightlifters: a case-control study. Am J Psychiatry. 2000;157(8):1291-1296.
250. Hildebrandt T, Alfano L, Langenbucher JW. Body image disturbance in 1000 male appearance and performance enhancing drug users. J Psychiatr Res. 2010;44(13):841-846.
251. Pope CG, Pope HG, Menard W, Fay C, Olivardia R, Phillips KA. Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body Image. 2005; 2(4):395-400.
252. Rohman L. The relationship between anabolic androgenic steroids and muscle dysmorphia: a review. Eat Disord. 2009;17(3):187-199.
253. Kashkin KB, Kleber HD. Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA. 1989;262(22): 3166-3170.
254. Tan RS, Scally MC. Anabolic steroid-induced hypogonadism- towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009;72(6):723-728.
255. Llewellyn W. Anabolics. 10th ed. Jupiter, FL: Molecular Nutrition; 2011.
256. Pinna G, Agis-Balboa RC, Pibiri F, Nelson M, Guidotti A, Costa E. Neurosteroid biosynthesis regulates sexually dimorphic fear and aggressive behavior in mice. Neurochem Res. 2008;33(10):1990-2007.
257. Elfverson M, Johansson T, Zhou Q, Le Grevès P, Nyberg F. Chronic administration of the anabolic androgenic steroid nandrolone alters neurosteroid action at the sigma-1 receptor but not at the sigma-2 or NMDA receptors. Neuropharmacology. 2011;61(7):1172-1181.
258. Skuza G. Pharmacology of sigma (σ) receptor ligands from a behavioral perspective. Curr Pharm Des. 2012;18(7): 863-874.
259. Johansson T, Elfverson M, Zhou Q, Nyberg F. Allosteric modulation of the NMDAreceptor by neurosteroids in rat brain and the impact of long term morphine administration. Biochem Biophys Res Commun. 2010;401(4):504-508.
260. Arnedo MT, Salvador A, Martinez-Sanchis S, Gonzalez-Bono E. Rewarding properties of testosterone in intact male mice: a pilot study. Pharmacol Biochem Behav. 2000; 65(2):327-332.
261. Arnedo MT, Salvador A, Martínez-Sanchís S, Pellicer O. Similar rewarding effects of testosterone in mice rated as short and long attack latency individuals. Addict Biol. 2002;7:373-379.
262. Alexander GM, Packard MG, Hines M. Testosterone has rewarding affective properties in male rats: implications for the biological basis of sexual motivation. Behav Neurosci. 1994;108(2):424-428.
263. Wood RI. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front Neuroendocrinol. 2008;29(4):490-506; PMC 2585375.
264. Zaugg M, JAMAli NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. Journal of cellular physiology. 2001;187(1):90-95.
265. Abu-Shakra S, Alhalabi MS, Nachtman FC, Schemidt RA, Brusilow WS. Anabolic steroids induce injury and apoptosis of differentiated skeletal muscle. J Neurosci Res. 1997; 47(2):186-197.
266. D'Ascenzo S, Millimaggi D, Di Massimo C, et al. Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett. 2007;169(2):129-136.
267. Fanton L, Belhani D, Vaillant F, et al. Heart lesions associated with anabolic steroid abuse: Comparison of postmortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp Toxicol Pathol. 2009;61:317-323.
268. Vicencio JM, Estrada M, Galvis D, et al. Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications. Mine Rev Med Chem. 2011;11(5):390-398.
269. Janjic MM, Stojkov NJ, Andric SA, Kostic TS. Anabolicandrogenic steroids induce apoptosis and NOS2 (nitricoxide synthase 2) in adult rat Leydig cells following in vivo exposure. Reprod Toxicol. 2012;34(4):686-693.
270. Estrada M, Varshney A, Ehrlich BE. Elevated testosterone induces apoptosis in neuronal cells. J Biol Chem. 2006; 281(35):25492-25501.
271. Caraci F, Pistarà V, Corsaro A, et al. Neurotoxic properties of the anabolic androgenic steroids nandrolone and methandrostenolone in primary neuronal cultures. J Neurosci Res. 2011;89(4):592-600.
272. Cunningham RL, Giuffrida A, Roberts JL. Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cδ. Endocrinology. 2009; 150(12):5539-5548.
273. Pieretti S, Mastriota M, Tucci P, et al. Brain nerve growth factor unbalance induced by anabolic androgenic steroids in rats. Med Sci Sports Exerc. 2013;45(1):29-35.
274. Reyes-Fuentes A, Veldhuis JD. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol Metab Clin North Am. 1993;22(1):93-124.
275. Gårevik N, Strahm E, Garle M, et al. Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. J Steroid Biochem Mol Biol. 2011;127:295-300.
276. van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamicpituitary dysfunction: a case study. Int J Sports Med. 2003; 24(3):195-196.
277. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril. 2003; 79(Suppl 3):1659-1661.
278. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108:1860-1865.
279. Boregowda K, Joels L, Stephens JW, Price DE. Persistent primary hypogonadism associated with anabolic steroid abuse. Fertil Steril. 2011;96(1):e7-e8.
280. Tan RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril. 2003;79(1):203-205.
281. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003; 15(3):156-165.
282. Takayanagi A, Kobayashi K, Hashimoto K, et al. Case of androgenic anabolic steroid abuse caused hypogonado- tropic hypogonadism [in Japanese]. Nihon Hinyokika Gakkai Zasshi. 2008;99(7):729-732.
283. Crampin AC, Lamagni TL, Hope VD, Newham JA, Lewis KM, Parry JV, Gill ON. The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales. Epidemiol Infect. 1998;121(2):381-386.
284. Sklarek HM, Mantovani RP, Erens E, Heisler D, Niederman MS, Fein AM. AIDS in a bodybuilder using anabolic steroids. N Engl J Med. 1984;311(26):1701.
285. Scott MJ, Scott MJ Jr. HIV infection associated with injections of anabolic steroids. JAMA. 1989;262(2):207-208.
286. Henrion R, Mandelbrot L, Delfieu D. HIV contamination after injections of anabolic steroids [in French]. Presse Med. 1992;21(5):218.
287. Rich JD, Dickinson BP, Merriman NA, Flanigan TP. Hepatitis C virus infection related to anabolic-androgenic steroid injection in a recreational weight lifter. Am J Gastroenterol. 1998;93(9):1598.
288. Nemechek PM. Anabolic steroid users-another potential risk group for HIV infection. N Engl J Med. 1991;325(5): 357.
289. Bolding G, Sherr L, Maguire M, Elford J. HIV risk behaviours among gay men who use anabolic steroids. Addiction. 1999;94(12):1829-1835.
290. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000; 75(4):386-394.
291. Isacsson G, Garle M, Ljung EB, Asgård U, Bergman U. Anabolic steroids and violent crime-an epidemiological study at a jail in Stockholm, Sweden. Compr Psychiatry. 1998;39(4):203-205.
292. Lood Y, Eklund A, Garle M, Ahlner J. Anabolic androgenic steroids in police cases in Sweden 1999-2009. Forensic Sci Int. 2012;219(1-3):199-204.
293. Baillargeon J, Black SA, Leach CT, et al. The infectious disease profile of Texas prison inmates. Prev Med. 2004; 38(5):607-612.
294. Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. Prevalence of infection with hepatitis B and Cviruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2009;86(1):93-105.
295. MacDougall DS. HIV/AIDS behind bars. J Int Assoc Physicians AIDS Care. 1998;4(4):8-13.
296. Mahon N. New York inmates' HIV risk behaviors: the implications for prevention policy and programs. Am J Public Health. 1996;86(9):1211-1215.
297. Rothon DA, Mathias RG, Schechter MT. Prevalence of HIV infection in provincial prisons in British Columbia. CMAJ. 1994;151(6):781-787.
298. Centers for Disease Control and Prevention (CDC). Methicillin- resistant Staphylococcus aureus infections among competitive sports participants - Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR. 2003;52:793-795.
299. Lloyd-Smith E, Hull MW, Tyndall MW, et al. Communityassociated methicillin-resistant Staphylococcus aureus is prevalent in wounds of community-based injection drug users. Epidemiol Infect. 2010;138(5):713-720.
300. Evans NA. Local complications of self administered anabolic steroid injections. Br J Sports Med. 1997;31(4):349-350.
301. Rich JD, Dickinson BP, Flanigan TP, Valone SE. Abscess related to anabolic-androgenic steroid injection. Med Sci Sports Exerc. 1999;31(2):207-209.
302. Palacios A, Campfield LA, McClure RD, Steiner B, SwerdloffRS. Effect of testosterone enanthate on hematopoiesis in normal men. Fertil Steril. 1983;40(1):100-104.
303. Maggio M, Snyder PJ, Ceda GP, et al. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology. 2013;1(1): 24-28.
304. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point [published online October 24, 2013]. J GerontolABiol Sci Med Sci. doi:10.1093/gerona/glt154.
305. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone- induced erythrocytosis. J Clin Endocrinol Metab. 2010;95(10):4743-4747.
306. Guo W, Bachman E, Li M, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12(2):280-291.
307. Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? J Am Osteopath Assoc. 2001;101(7):391-394.
308. Daniels JM, van Westerloo DJ, de Hon OM, Frissen PH. Rhabdomyolysis in a bodybuilder using steroids [in Dutch]. Ned Tijdschr Geneeskd. 2006;150(19):1077-1080.
309. Hageloch W, Appell HJ, Weicker H. Rhabdomyolysis in a bodybuilder using anabolic steroids [in German]. Sportverletz Sportschaden. 1988;2(3):122-125.
310. Adamson R, Rambaran C, D'Cruz DP. Anabolic steroidinduced rhabdomyolysis. Hosp Med. 2005;66(6):362.
311. Braseth NR, Allison EJ Jr, Gough JE. Exertional rhabdomyolysis in a body builder abusing anabolic androgenic steroids. Eur J Emerg Med. 2001;8(2):155-157.
312. Winnett G, Cranfield L, Almond M. Apparent renal disease due to elevated creatinine levels associated with the use of boldenone. Nephrol Dial Transplant. 2011;26(2): 744-747.
313. Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21:163-172.
314. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet. 1977;2(8032):262-263.
315. Karasawa T, Shikata T, Smith RD. Peliosis hepatis. Report of nine cases. Acta Pathol Jpn. 1979;29(3):457-469.
316. Schumacher J, Müller G, Klotz KF. Large hepatic hematoma and intraabdominal hemorrhage associated with abuse of anabolic steroids. N Engl J Med. 1999;340(14): 1123-1124.
317. Daneshmend TK, Bradfield JW. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet. 1979; 2(8154):1249.
318. Falk H, Thomas LB, Popper H, Ishak KG. Hepatic angio- sarcoma associated with androgenic-anabolic steroids. Lancet. 1979;2(8152):1120-1123.
319. Bagia S, Hewitt PM, Morris DL. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust N Z J Surg. 2000;70(9):686-687.
320. Nakao A, Sakagami K, Nakata Y, et al. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol. 2000; 35(7):557-562.
321. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol. 2004;77(3):257-267.
322. Gorayski P, Thompson CH, Subhash HS, Thomas AC. Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med. 2008;42(1):74-75; discussion 75.
323. Carrasco D, Prieto M, Pallardó L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature. J Hepatol. 1985;1(6):573-578.
324. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep. 2006;5(2):104-109.
325. Neri M, Bello S, Bonsignore A, et al. Anabolic androgenic steroids abuse and liver toxicity. Mine Rev Med Chem. 2011;11(5):430-437.
326. Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65(2):253-259.
327. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med. 1999;9(1):34-39.
328. Nikolopoulos DD, Spiliopoulou C, Theocharis SE. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents. Fundam Clin Pharmacol. 2011;25(5):535-563.
329. Horn S, Gregory P, Guskiewicz KM. Self-reported anabolic- androgenic steroids use and musculoskeletal injuries: findings from the center for the study of retired athletes health survey of retired NFL players. Am J Phys Med Rehab. 2009;88(3):192-200.
330. Laseter JT, Russell JA. Anabolic steroid-induced tendon pathology: a review of the literature. Med Sci Sports Exerc. 1991;23(1):1-3.
331. Stannard JP, Bucknell AL. Rupture of the triceps tendon associated with steroid injections. AmJ Sports Med. 1993; 21(3):482-485.
332. Visuri T, Lindholm H. Bilateral distal biceps tendon avulsions with use of anabolic steroids. Med Sci Sports Exerc. 1994;26(8):941-944.
333. David HG, Green JT, Grant AJ, Wilson CA. Simultaneous bilateral quadriceps rupture: a complication of anabolic steroid abuse. J Bone Joint Surg. 1995;77(1):159-160.
334. Lambert MI, St Clair Gibson A, Noakes TD. Rupture of the triceps tendon associated with steroid injections. Am J Sports Med. 1995;23(6):778.
335. Liow RY, Tavares S. Bilateral rupture of the quadriceps tendon associated with anabolic steroids. Br J Sports Med. 1995;29(2):77-79.
336. Sollender JL, Rayan GM, Barden GA. Triceps tendon rupture in weight lifters. J Shoulder Elbow Surg. 1998;7(2): 151-153.
337. Cope MR, Ali A, Bayliss NC. Biceps rupture in body builders: three case reports of rupture of the long head of the biceps at the tendon-labrum junction. J Shoulder Elbow Surg. 2004;13(5):580-582.
338. Evans NA, Bowrey DJ, Newman GR. Ultrastructural analysis of ruptured tendon from anabolic steroid users. Injury. 1998;29(10):769-773.
339. Michna H. Organisation of collagen fibrils in tendon: changes induced by an anabolic steroid. I. Functional and ultrastructural studies. Virchows Archiv. 1986;52(1):75-86.
340. Wood TO, Cooke PH, Goodship AE. The effect of exercise and anabolic steroids on the mechanical properties and crimp morphology of the rat tendon. Am J Sports Med. 1988;16(2):153-158.
341. Inhofe PD, Grana WA, Egle D, Min KW, Tomasek J. The effects of anabolic steroids on rat tendon. An ultrastructural, biomechanical, and biochemical analysis. Am J Sports Med. 1995;23(2):227-232.
342. Brenu EW, McNaughton L, Marshall-Gradisnik SM. Is there a potential immune dysfunction with anabolic androgenic steroid use?: A review. Mine Rev Med Chem. 2011;11(5):438-445.
343. Vougiouklakis T, Mitselou A, Batistatou A, Boumba V, Charalabopoulos K. First case of fatal pulmonary peliosis without any other organ involvement in a young testosterone abusing male. Forensic Sci Int. 2009;186(1-3):e13-16.
344. Kraus SL, Emmert S, Schön MP, Haenssle HA. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. 2012;148(10): 1210-1212.
345. Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B, Wirth MP. Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report. Cancer. 1999;86(8):1571-1575.
346. Martorana G, Concetti S, Manferrari F, Creti S. Anabolic steroid abuse and renal cell carcinoma. J Urol. 1999; 162(6):2089.
347. Bryden AA, Rothwell PJ, O'Reilly PH. Anabolic steroid abuse and renal-cell carcinoma. Lancet. 1995;346(8985): 1306-1307.
348. Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet. 1986;2(8509):742.
349. Larkin GL. Carcinoma of the prostate. N Engl J Med. 1991;324(26):1892.
350. Wiesing U. Should performance-enhancing drugs in sport be legalized under medical supervision? Sports Med. 2011; 41(2):167-176.
351. Shuster S, Devine JW. The banning of sportsmen and women who fail drug tests is unjustifiable. J R Coll Physicians Edinb. 2013;43(1):39-43.
352. Savulescu J, Foddy B, Clayton M. Why we should allow performance enhancing drugs in sport. Br J Sports Med. 2004;38(6):666-670.
353. Donike M, Barwald KR, Klostermann K, Schanzer W, Zimmermann J. The detection of exogenous testosterone. In: Liesen H, Rost R, eds. Sport: Leistung Gesundheit. Cologne, Germany: Deutscher Arzte; 1982;293-298.
354. Baenziger J, Bowers LD. Variability of T/E ratios in athletes. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. Recent Advances in Doping Analysis. Vol 2. Köln, Germany: Sport und Buch Strauss; 1994: 41-52.
355. Sottas PE, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics. 2007;8(2):285-296.
356. Chen EY, Liao YC, Smith DH, Barrera-Saldaña HA, Gelinas RE, Seeburg PH. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics. 1989;4(4):479-497.
357. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekström L, Rane A. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab. 2008;93(7):2500-2506.
358. Anielski P, Simmchen J, Wassill L, Ganghofner D, Thieme D. Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios. Drug Test Anal. 2011;3(10):645-651.
359. Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83(3):337-346.
360. Becchi M, Aguilera R, Farizon Y, Flament MM, Casabianca H, James P. Gas chromatography/combustion/isotope- ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Communications in Mass Spectrometry. 1994;8(4):304-308.
361. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
362. Kicman AT. Biochemical and physiological aspects of endogenous androgens. Handb Exp Pharmacol. 2010;195: 25-64.
363. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001-1020.
364. Horning S, Hoehn M, Muenster H, Geyer H, Schänzer W. GC/HRMS-ION TRAP screening and confirmation of anabolic steroids. Paper presented at 16th Cologne Workshop on Dope Analysis; March 15-20, 1998; Cologne, Germany.
365. Thevis M, Makarov AA, Horning S, Schänzer W. Mass spectrometry of stanozolol and its analogues using electrospray ionization and collision-induced dissociation with quadrupole-linear ion trap and linear ion trap-orbitrap hybrid mass analyzers. Rapid Commun Mass Spectrom. 2005;19(22):3369-3378.
366. Geyer H, Parr MK, Koehler K, Mareck U, Schänzer W, Thevis M. Nutritional supplements cross-contaminated and faked with doping substances. J Mass Spectrom. 2008; 43(7):892-902.
367. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382-395.
368. Baumann GP. Growth hormone doping in sports: a critical review of use and detection strategies. Endocr Rev. 2012; 33(2):155-186.
369. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev. 1991;12(4):424-449.
370. Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med. 2008;148(10):747-758.
371. Rennie MJ. Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes? Br J Sports Med. 2003;37(2):100-105.
372. Birzniece V, Nelson AE, Ho KK. Growth hormone and physical performance. Trends Endocrinol Metab. 2011; 22(5):171-178.
373. Pipe A. Growth hormone temporarily improves sprint capacity in recreational athletes. Clin J Sport Med. 2011; 21(4):369-370.
374. Meinhardt U, Nelson AE, Hansen JL, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med. 2010;152(9):568-577.
375. Woodhouse LJ, Asa SL, Thomas SG, Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab. 1999; 84(12):4570-4577.
376. Wass JA, Trainer PJ, Korbonits M. Acromegaly. In: Wass J, Stewart P, eds. Oxford Textbook of Endocrinology and Diabetes. 2nd ed. Oxford, UK: Oxford Press; 2011;197-209.
377. Dutta P, Bhansali A, Vaiphei K, et al. Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis? Pituitary. 2012;15(2):166-173.
378. Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf). 1997;47(1):17-22.
379. Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3218-3221.
380. Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf). 2005;63(2):161-167.
381. Bidlingmaier M, Suhr J, Ernst A, et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem. 2009;55(3):445-453.
382. Wallace JD, Cuneo RC, Bidlingmaier M, et al. Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GHin trained adult males. J Clin Endocrinol Metab. 2001; 86(4):1731-1737.
383. Erotokritou-Mulligan I, Guha N, Stow M, et al. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal propeptide of type III collagen assays. Growth Horm IGF Res. 2012;22(2):53-58.
384. Wallace JD, Cuneo RC, Lundberg PA, et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab. 2000;85(1): 124-133.
385. Azzazy HM, Mansour MM, Christenson RH. Gene doping: of mice and men. Clin Biochem. 2009;42(6):435-441.
386. Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids inhumanskeletal muscle. J Clin Invest. 1995;95(2):811-819.
387. Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol. 2008;154(3):529-541.
388. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324(19): 1339-1344.
389. Fisher LM. Stamina-building drug linked to athletes. New York Times. May 19, 1991. http://www.nytimes.com/1991/05/19/us/stamina-building-drug-linked-to-athletesdeaths. html. Accessed January 30, 2013.
390. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature. 2000;405(6787):635.
391. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem. 2002;311(2):119-126.
392. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology. 1991;1(4):337-346.
393. Reichel C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T. SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal. 2009;1(1): 43-50.
394. Morkeberg J, Sharpe K, Karstoft K, Ashenden MJ. Detection of microdoses of rhEPO with the MAIIA test [published online January 24, 2013]. Scand J Med Sci Sports. doi:10.1111/sms.12049.
395. Lönnberg M, Drevin M, Carlsson J. Ultra-sensitive immunochromatographic assay for quantitative determination of erythropoietin. J Immunol Methods. 2008;339(2):236-244.
396. Schumacher YO, Saugy M, Pottgiesser T, Robinson N. Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal. 2012;4(11):846-853.
397. Zorzoli M, Rossi F. Case studies on ESA-doping as revealed by the Biological Passport. Drug Test Anal. 2012; 4(11):854-858.
398. Monfort N, Ventura R, Platen P, et al. Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion. 2012;52(3):647-657.
399. Segura J, Monfort N, Ventura R. Detection methods for autologous blood doping. Drug Test Anal. 2012;4(11): 876-881.
400. DeKosky ST, Ikonomovic MD, Gandy S. Traumatic brain injury-football, warfare, and long-term effects. N Engl J Med. 2010;363(14):1293-1296.
401. Steroid test results. Army Substance Abuse Program. Washington, DC: U.S. Army; 2012:3.
402. Nuñez J. Sex and steroid hormones in early brain injury. Rev Endocr Metab Disord. 2012;13(3):173-186.
403. Vagnerova K, Koerner IP, Hurn PD. Gender and the injured brain. Anesth Analg. 2008;107(1):201-214.
404. van der Gronde T, de Hon O, Haisma HJ, Pieters T. Gene doping: an overview and current implications for athletes. Br J Sports Med. 2013;47(11):670-678.
405. Sweeney HL. Gene doping. Sci Am. 2004;291(1):62-69.
406. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12(5):316-328.
407. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341-355.
408. Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29(2):121-128.
409. Carpentier AC, Frisch F, Labbé SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635-1644.
410. Tian G, Liu J, Sui J. A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. Anticancer Drugs. 2009;20(5): 403-407.
411. Svensson EC, Black HB, Dugger DL, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replicationdefective adenoviral vector. Hum Gene Ther. 1997;8(15): 1797-1806.
412. Binley K, Askham Z, Iqball S, et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood. 2002;100(7):2406-2413.
413. Puskovic V, Wolfe D, Wechuck J, et al. HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther. 2006;14(5):710-715.
414. Musarò A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2): 195-200.
415. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586-623.
416. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004;20:61-86.
417. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682-2688.
418. Vogel G. Mighty mice: inspiration for rogue athletes? Science. 2004;305(5684):633.
419. Lee SJ. Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet. 2007;23(10):475-477.
420. Moser DA, Neuberger EW, Simon P. A quick one-tube nested PCR-protocol for EPO transgene detection. Drug Test Anal. 2012;4(11):870-875.
421. Neuberger EW, Jurkiewicz M, Moser DA, Simon P. Detection of EPO gene doping in blood. Drug Test Anal. 2012;4(11):859-869.